Starpharma's VivaGel Phase 3 trials 60% enrolled
4 June 2012
Melbourne Australia: Starpharma Holdings Ltd (ASX:SPL, OTCQX: SPHRY) is pleased to report excellent progress in the recruitment for its pivotal Phase 3 trials for VivaGel® as a treatment for bacterial vaginosis (BV).
Key points
- Enrolment passes 60% for VivaGel® Phase 3 BV treatment trials
- Trials well on track for completion in 2012
- One of the trials has already enrolled more than 80% of subjects
Two concurrent Phase 3 trials are underway and recruitment for these trials, which commenced in late March 2012, has recently passed the halfway mark with 60% of patients already enrolled. One of the trials has already exceeded 80% enrolment.